期刊文献+

二甲双胍调控AKT/MDR-1增强人结肠癌细胞HT-29对5-FU药物敏感性机制探讨 被引量:4

Metformin reserves the drug resistance of 5-FU in HT-29 human colon carcinoma cells through regulation of AKT/ MDR-1
下载PDF
导出
摘要 目的:探究二甲双胍增强化疗药物5-氟尿嘧啶(5-FU)对人结肠癌细胞株HT-29细胞毒的相关机制。方法:体外培养人结肠癌细胞株HT-29,以5-FU联合或不联合二甲双胍干预细胞,MTT法检测细胞增殖情况;流式细胞仪检测细胞凋亡;Lipofectmin 2000转染AKT质粒;RT-PCR法检测AKT、MDR-1核酸表达;Western Blot法检测AKT、p-AKT、MDR-1蛋白表达。结果:二甲双胍能够增强5-FU对HT-29细胞增殖的抑制作用,单用5-FU与5-FU联合二甲双胍干预的细胞早期及晚期凋亡率分别为(50.12±5.96)%和(78.00±3.39)%,差异具有统计学意义(P<0.05)。二甲双胍可以在核酸及蛋白的水平上下调AKT、pAKT及MDR-1水平;过表达AKT单独5-FU处理较空白质粒组凋亡率降低(19.72±2.23)%,过表达联合用药组凋亡率较空白质粒组降低(20.30±3.15)%,差异具有统计学意义(P<0.05)。结论:二甲双胍通过调节AKT/MDR-1增强人结肠癌细胞HT-29对5-FU的药物敏感性。 Objective:To explore the mechanism of that mefformin enhances the cytotoxicity of 5 -fluorouracil (5 - FU ) to human colon cancer cell line HT - 29. Methods: Treating the HT - 29 cells with 5 - FU with or without mefformin. MTF assay to analyze the cell proliferation ,flow eytometry to detect apoptosis. Lipofectmin 2000 transfected AKT plasmid. RT - PCR to detect the nucleic acid expression level of AKT, MDR - 1. Western Blot to check the pro- tein expression level of AKT, p - AKT and MDR - 1. Results: Compared with the single - agent 5 - FU, mefformin can enhance 5 - FU on inhibiting the proliferation of HT - 29 cells. The apoptosis rates for single - agent and double - agent were ( 50.12 ± 5.96) % and (78.00± 3.39 ) %, respectively ( P 〈 0.05 ). Mefformin may down - regulate the p - AKT and MDR - 1 levels in both nucleic acid and protein levels. While overexpressed of AKT,for the 5 - FU sin- gle - agent, apoptotic rate was decreased ( 19.72 ± 2.23 ) % than negative control plasmid,and for combination,it also decreased (20.30 ±3.15 ) % ( P 〈 0.05 ). Conclusion: By regulating AKT/MDR - 1 pathway, metformin enhances the drug sensitivity of 5 -FU to human colon cancer cell line HT- 29.
出处 《现代肿瘤医学》 CAS 2015年第24期3560-3564,共5页 Journal of Modern Oncology
关键词 结直肠癌 二甲双胍 AKT MDR-1 colorectal cancer, metformin, AKT, MDR - 1
  • 相关文献

参考文献10

  • 1Xiao B, Zhang M, Viennois E, et al. Inhibition of MDR1 gene ex- pression and enhancing cellular uptake for effective colon cancer treatment using dual - surface - functionalized nanoparticles [ J ]. Biomaterials ,2015,48 (4) : 147 - 160.
  • 2Davies MA. Regulation, role, and targeting of Akt in cancer [ J ]. J Clin Onco1,2011,29 ( 35 ) :4715 - 4717.
  • 3Marzolini C,Paus E,Buclin T,et al. Polymophisms in human MDR - 1 ( P - glyeoprotein ) : Recent advances and clinical relevance [J]. Clin Phamacol Ther,2004,75 ( 1 ) :13 -20.
  • 4Fujimaki S, Funato T, Harigae H, et al. Quantitative analysis of a MDR1 transcript for prediction of drug resistance in acute leukemia [J]. Clin Chem,2002,48(6 Pt 1) :811 -817.
  • 5Chen S,Huo X,Lin Y,et al. Association of MDR1 and ERCC1 pol- ymorphisms with response and toxicity to cisplatin - based chemo- therapy in non - small - cell lung cancer patients [ J ]. Int J Hyg Environ Health ,2010,213 (2) : 140 - 145.
  • 6Lee JH,Kim TI,Jeon SM,et al. The effects of metformin on the sur- vival of colorectal cancer patients with diabetes mellitus [ J ]. Int J Cancer,2011,131(3) :752 -759.
  • 7邵淑丽,李旭艳,张伟伟,恽东泽,付博,张珍珠.沉默MDR1基因增强急性早幼粒白血病耐药细胞HT9药物敏感性[J].中国细胞生物学学报,2012,34(10):983-987. 被引量:4
  • 8冯婉婷,车晓玲,李进,宗明珠,史玉叶,曹维克,何敬东.人结直肠癌耐药细胞株HT-29/CPT-11的构建及其生物学特性探讨[J].东南大学学报(医学版),2012,31(1):31-35. 被引量:5
  • 9Ferreira GD, Germeyer A, De Barros Machado A, et al. Metformin modulates PI3K and GLUT4 expression and Akt/PKB phosphoryla- tion in human endometrial stromal cells after stimulation with an- drogen and insulin [ J ]. Eur J Obstet Gynecol Reprod Biol, 2014, 175(4) :157 - 162.
  • 10Hu XF, Li J, Yang E, et al. Anti - Cripto Mab inhibit tumor growth and overcome MDR in a human leukaemia MDR cell line by inhi- bition of Akt and activation of JNK/SAPK and bad death pathways [J]. Sr J Cancer,2007,96(6) :918 -927.

二级参考文献12

  • 1常宏宇,潘凯丽.白血病多药耐药逆转研究进展[J].细胞与分子免疫学杂志,2005,21(B03):101-102. 被引量:10
  • 2高丽萍,魏虎来,景涛,吴勇杰,陈静,孙静,易娟,赵怀顺.siRNA抑制K562/ADM细胞mdr1基因表达并逆转其耐药性[J].中国癌症杂志,2007,17(1):58-61. 被引量:4
  • 3JEMAL A,SIEGEL R,WARD E,et al.Cancer statistics[J].CA Cancer J Clin,2008,58(2):71-96.
  • 4INNOCENTI F,KROETZ D L,SCHUETZ E,et al.Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics[J].J Clin Oncol,2009,27(16):2604-2614.
  • 5ROUGIER P,MITRY E.Colorectal cancer chemotherapy:irinotecan[J].Semin Oncol,2000,27:138-143.
  • 6GILLET J P,EFFERTH T,REMACLE J.Chemotherapy-induced resistance by ATP-binding cassette transporter genes[J].Biochim Biophys Acta,2007,1775(2):237-262.
  • 7ECKFORD P D W,SHAROM F J.ABC efflux pump based resistance to chemotherapy drugs[J].Chem Rev,2009,109:2989-3011.
  • 8LO H W,ALI-OSMAN F.Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance[J].Curr Opin Pharmacol,2007,7(4):367-374.
  • 9FERGUSON D O,ALT F W.DNA double strand break repair and chromosomal translocation:lessons from animal models[J].Oncogene,2001,20(40):5572-5579.
  • 10HARGUINDEY S,ORIVE G,LUIS PEDRAZ J,et al.The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer.Two faces of the same coin-one single nature[J].Biochim Biophys Acta,2005,1756(1):1-24.

共引文献7

同被引文献26

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部